Work

Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2560

Authors: Diwakar Davar, Justin C Moser, Michael Millward, Mark Voskoboynik, Nehal J. Lakhani, Rachel E. Sanborn, Jaspreet Singh Grewal, Ajita Narayan, Mario Sznol, Stacey R. Dillon, Keren Schieber, Hany Zayed, Christine Marie Dela Cruz, Graciela Noemi Perez, Stanford L. Peng

Institutions: UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, HonorHealth, The University of Western Australia, Linear Clinical Research, The Alfred Hospital, Monash University, Providence Portland Medical Center, Norton Healthcare, Yale New Haven Hospital, Yale Cancer Center, Yale University, Smilow Cancer Hospital, Alpine Immune Sciences (United States), Bristol-Myers Squibb (United States), PRA Health Sciences

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281715218

Cites:

Cited by: 2

Related to: 10